The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Thyroid Function and Mortality in Patients Treated for Hyperthyroidism
Abstract
CONTEXT: Hyperthyroidism has been reported to cause excess all-cause and circulatory mortality. Whether this can be reversed is unknown, as is the influence of mild persisting thyroid dysfunction and treatment-induced hypothyroidism. OBJECTIVES: To determine whether radioiodine treatment is associated with increased mortality and to determine the influences of mild thyroid dysfunction and the development of overt hypothyroidism treated with thyroxine (T(4)). DESIGN, SETTING, AND PARTICIPANTS: A population-based study of 2668 individuals aged 40 years or older treated for overt hyperthyroidism with radioiodine in the West Midlands region of England from 1984-2002. MAIN OUTCOME MEASURES: Cause of death compared with age- and period-specific mortality in England and Wales and assessment of the influence of T(4) therapy for radioiodine-induced hypothyroidism and subclinical thyroid dysfunction on mortality. RESULTS: In 15,968 person-years of follow-up, 554 died vs 487 expected deaths (standardized mortality ratio [SMR], 1.14; 95% confidence interval [CI], 1.04-1.24, P=.002). Increased risks of all-cause and circulatory deaths vs age- and period-specific mortality were observed in follow-up in those not requiring, or prior to, T(4) therapy. These increased risks were not observed during follow-up on T(4) therapy (circulatory disease SMR prior to T(4), 1.33; 95% CI, 1.14-1.53 vs SMR, 0.91; 95% CI, 0.70-1.17 during T(4)). Patients receiving T(4) had decreased risk of mortality vs risk in the period not requiring, or prior to, T(4) therapy (all-cause mortality hazard ratio [HR], 0.65; 95% CI, 0.54-0.79; circulatory mortality HR, 0.65; 95% CI, 0.48-0.87). Increased all-cause mortality vs the background population was observed in the period prior to T(4) therapy in follow-up associated with low, normal, and high serum thyrotropin. The SMR for ischemic heart disease increased slightly when analyzed by serum thyrotropin, high serum thyrotropin being the highest SMR (low thyrotropin SMR, 1.06; 95% CI, 0.75-1.45; normal thyrotropin SMR, 1.17; 95% CI, 0.76-1.71; high thyrotropin SMR, 1.48; 95% CI, 0.86-2.37). Comparison within the cohort showed that mild hypothyroidism prior to T(4) therapy was associated with increased risk of mortality from ischemic heart disease vs biochemical euthyroidism (HR, 2.08; 95% CI, 1.04-4.19). CONCLUSIONS: Patients treated with radioiodine for hyperthyroidism had increased mortality vs age- and period-specific mortality in England and Wales, a finding no longer evident during T(4) therapy. This supports treating hyperthyroidism with doses of radioiodine sufficient to induce overt hypothyroidism. The association within the cohort of mortality from ischemic heart disease with subclinical hypothyroidism suggests T(4) replacement should be considered should this biochemical abnormality develop after radioiodine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons
Sawin, C. T., Geller, A., Wolf, P. A., Belanger, A. J., Baker, E., Bacharach, P., Wilson, P., Benjamin, E. J., & D'Agostino, R. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311901 · Cited by 1,259 · cited 1×
“The present findings add to the current debate about the cardiovascular consequences of subclinical hyperthyroidism—which was prompted by the finding of a 3-fold increased incidence of atrial fibrillation during a 10-year follow-up of those with low serum thyrotropin levels identified among those older than 60 years i…”
ResultThyroid Status, Disability and Cognitive Function, and Survival in Old Age
Gussekloo, J. (2004) · JAMA · doi:10.1001/jama.292.21.2591 · Cited by 899 · cited 1×
“Other studies have, however, failed to demonstrate an increase in vascular morbidity or mortality associated with subclinical hypothyroidism, including the Cardiovascular Health Study involving 3768 participants,(6) a 20-year follow-up of 2779 participants in the Whickham cohort in the United Kingdom,(22) and a recent…”
BackgroundParle, J. V., Maisonneuve, P., Sheppard, M. C., Boyle, P., & Franklyn, J. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06067-6 · Cited by 669
Self-citationFade, J. V., Franklyn, J. A., Cross, K. W., Jones, S. C., & Sheppard, M. C. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb01739.x · Cited by 567
Self-citationSubclinical hyperthyroidism as a risk factor for atrial fibrillation
Auer, J., Scheibner, P., Mische, T., Langsteger, W., Eber, O., & Eber, B. (2001) · American Heart Journal · doi:10.1067/mhj.2001.119370 · Cited by 314
Thyrocardiac Disease and Its Management with Radioactive Iodine I131
Delit, C. (1961) · JAMA · doi:10.1001/jama.1961.03040170008003 · Cited by 21
Cited by
Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324
Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.3.456 · Cited by 1,098
The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Bahn, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0417 · Cited by 898
Thyroid hormones and cardiovascular disease
Jabbar, A., Pingitore, A., Pearce, S. H. S., Zaman, A., Iervasi, G., & Razvi, S. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.174 · Cited by 729
Brent, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801880 · Cited by 594
Flynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
Davies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Bonnema, S. J., & Hegedüs, L. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1030 · Cited by 339
Franklyn, J. A., & Boelaert, K. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60782-4 · Cited by 262
Self-citationCardiovascular involvement in patients with different causes of hyperthyroidism
Biondi, B., & Kahaly, G. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.105 · Cited by 230
Is there a need to redefine the upper normal limit of TSH?
Brabant, G., Beck-Peccoz, P., Jarzab, B., Laurberg, P., Orgiazzi, J., Szabolcs, I., Weetman, A. P., & Wiersinga, W. M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02136 · Cited by 211
Boelaert, K., Torlinska, B., Holder, R. L., & Franklyn, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2495 · Cited by 196
“3% of males (1) and is associated with significant morbidity and mortality, mainly from cardiovascular and cerebrovascular disease (2, 3).”
BackgroundSelf-citationHaentjens, P., Van Meerhaeghe, A., Poppe, K., & Velkeniers, B. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0110 · Cited by 174
A critical review and meta-analysis of the association between overt hyperthyroidism and mortality
Brandt, F., Green, A., Hegedüs, L., & Brix, T. H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0299 · Cited by 170
Thyrotropin Levels and Risk of Fatal Coronary Heart Disease: The HUNT Study
Åsvold, B. O., Bjøro, T., Nilsen, T. I. L., Gunnell, D., & Vatten, L. J. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.855 · Cited by 125
Völzke, H., Schwahn, C., Wallaschofski, H., & Dörr, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0179 · Cited by 120
Thyroid dysfunction in the elderly
Boelaert, K. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.30 · Cited by 84
Boelaert, K., Maisonneuve, P., Torlinska, B., & Franklyn, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3459 · Cited by 82
Self-citationPediatric Graves’ disease: management in the post-propylthiouracil Era
Rivkees, S. A. (2014) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2014-10 · Cited by 46
“These studies have not revealed increased mortality or increased rates of cancer following (131)I for GD [103-109].”
Background
Metadata
- Authors
- Franklyn, J. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-06
- Volume
- 294
- Issue
- 1
- Pages
- 71
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2052304058
- Cited by
- 186
- References
- 7
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.